ALVAC-CEA vaccine is a cancer vaccine containing a canary pox virus (ALVAC) combined with the carcinoembryonic antigen (CEA) human gene.
A phase I trial in 118 patients showed safety in humans.[1]
This article incorporates public domain material from the U.S. National Cancer Institute document "Dictionary of Cancer Terms".
| This oncology article is a stub. You can help Wikipedia by expanding it. |
| This vaccine article is a stub. You can help Wikipedia by expanding it. |
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)